Serial Determinations of Melanoma Tumor—Associated Antigen and Antibody in Patients With Stage I Melanoma

Wong, Jan H.; Gupta, Rishab K.; Morton, Donald L.

doi:10.1001/archsurg.1986.01400110134023

Cited by 9 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is generally agreed that TAA present in CIC of cancer patients comprise only a small fraction of the antigens complexed to antibodies [6]. Demonstration of the putative antigen and its relationship to disease has been achieved in certain malignancies including melanoma [31] and carcinoma of the lung [4].…”

Section: Discussionmentioning

confidence: 99%

Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients

et al. 1988

Cancer Immunol Immunother

View full text Add to dashboard Cite

A well-characterized 69.5 x 10(3) dalton glycoprotein fetal antigen (FA), isolated from the spent culture medium of a melanoma cell line, UCLA-SO-14 (M14), was utilized to characterize the antigen component of circulating immune complexes (CIC) from melanoma patients. Ten serum samples from five patients with stage II melanoma at 1 and 4 months prior to the clinical detection of recurrent disease were selected for study. The CIC were dissociated with low pH and ultrafiltered through a 100 x 10(3) dalton exclusion limit membrane. The low pH treatment resulted in an increase in antibody titer in eight of ten serum samples. The antibody activity in membrane immunofluorescence was quantitatively inhibited by the filtered antigen fraction and purified FA, suggesting the presence of anti-FA antibodies in the treated serum, which possibly were complexed with FA in the untreated sample. As determined by competitive inhibition in an enzyme-linked immunosorbent assay, the filtrate (antigen fraction) contained an antigen that was immunologically similar to FA. These results clearly demonstrate that FA, expressed on the cell surface of melanoma cells, is present in CIC of selected melanoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients

et al. 1988

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

Tumor-Associated Antigen Immune Complexes

Wong

Xu²,

Gupta³

et al. 1990

Arch Surg

View full text Add to dashboard Cite

Prospective Evaluation of the Use of Antigen-Specific Immune Complexes in Predicting the Development of Recurrent Melanoma

Wong

Xu²,

Escandón³

et al. 1991

Arch Surg

View full text Add to dashboard Cite

We previously demonstrated that the antigen-specific immune complexes captured by the monoclonal antibody MAb JSI in a sandwich enzyme-linked immunosorbent assay were associated with recurrent melanoma. To determine the potential use of antigen-specific immune complex analysis in predicting the development of recurrent melanoma, we prospectively analyzed serum obtained from patients with melanoma following surgical treatment. Two hundred fifty-three patients have been followed up for a median of 25 months (range, 17 to 29 months). Seventy-seven patients (30%) have developed recurrent melanoma. Antigen-specific immune complexes correlated with the stage of disease at time of entry into the study. The absence of antigen-specific immune complexes in postoperative serum samples is predictive of a disease-free status. Long-term follow-up will define the false-positive rate of antigen-specific immune complex analysis. Continued refinement of this approach should lead to clinically useful methodology to monitor human melanoma.

show abstract

Serial Determinations of Melanoma Tumor—Associated Antigen and Antibody in Patients With Stage I Melanoma

Cited by 9 publications

References 19 publications

Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients

Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients

Tumor-Associated Antigen Immune Complexes

Prospective Evaluation of the Use of Antigen-Specific Immune Complexes in Predicting the Development of Recurrent Melanoma

Contact Info

Product

Resources

About